Treatment selection for patients with metastatic renal cell carcinoma: identification of features favoring upfront IL-2-based immunotherapy.

Medical oncology (Northwood, London, England)

Volumn 26 Suppl 1, Issue , 2009, Pages 18-22

  Atkins, Michael B ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; INTERLEUKIN 2;

CLINICAL TRIAL; HUMAN; IMMUNOLOGY; IMMUNOTHERAPY; KIDNEY CARCINOMA; KIDNEY TUMOR; METASTASIS; PATHOLOGY; PATIENT SELECTION; REVIEW;

ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; CLINICAL TRIALS AS TOPIC; HUMANS; IMMUNOTHERAPY; INTERLEUKIN-2; KIDNEY NEOPLASMS; PATIENT SELECTION;

EID: 64549156573     PISSN: 13570560     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12032-008-9148-x     Document Type: Review

References (17)